Author Archive | Raynovich Rod

“January Effect” Traders: Take Some Profits

If you followed our trades from November /December you made at least 20% so why push it? The Rayno Life Science Portfolio is down 0.75% today in a choppy  market. Our mid-cap biopharmaceutical index is down 0.87% but diagnostics and tools are  down only 0.3% as they were hit hard over the past 3 months. […]

Continue Reading 0

“January Effect” Rolls On with Biotech Stocks Up Over 1%, 9.3% MTD

Seems a Bit Frothy Large and mid-cap biopharmaceutical stocks continued to surge today with the bellwether ETF IBB ($114) hitting one year highs of $114.15 today. Many of our recent focus picks also continue to roll ahead: Astex (ASTX $2.18) up 4.8%, Gilead (GILD $47.40) up 2.4%,ImmunoGen (IMGN $12.75) up 3.3%, Seattle Genetics (SGEN $18) up […]

Continue Reading 0

Trends from the JPMorgan Healthcare Conference 2012

Healthcare: Broad Trends and Business Concepts for 2012 Last year we published an overview of trends for the 2011 JPMorgan Conference. Here is a very brief review from this year’s Conference: The lagging Life Science Tools sector was ignited by new sequencing and genetic analysis products from Life Technologies (LIFE) and Illumina (ILMN). NIH and […]

Continue Reading 0

“January Effect” Rally: A Cliched Trade That Really Works

You read about it every year, and always there are skeptics, but in Q4 2011 to Q 2012 the “January effect ” rally for small cap and life science stocks were big winners. Why does this happen? Not so important just that it does happen. Here are our December focus picks (see earlier posts):   […]

Continue Reading 0

JPMorgan Healthcare Conference: Life Science Tools Rally

Life Science stocks got a boost from news and presentations at the J.P.Morgan Healthcare Conference and most stocks from the Rayno Life Science Portfolio were up.(see our “January Effect” trades mentioned in December). Leading life science tools companies Illumina (ILMN $34) up 3% again today,and Life Technologies (LIFE $46.28) were boosted by new product announcements, new […]

Continue Reading 0

Rayno SnowBlog: High and Dry- Dry Curse of La Nina is Back 1/31

We had a powder weekend in Mammoth with 3ft Jan20-22 but nothing on the horizon for 10 days. Check Alta, Northwest like Mt Baker or BC and maybe Big Sky. http://www.cpc.ncep.noaa.gov/products/predictions/814day/814day.02.gif http://weather.unisys.com/gfsx/gfsx.php?inv=0&plot=hght&region=us&t=5d http://weather.unisys.com/gfsx/gfsx.php?inv=0&plot=hght&region=nh&t=7d ————— The forecasters have turned on the WHITE. Howard Sheckter calls the turn and end of  the abysmal sunshine! San Francisco Weekend Weather […]

Continue Reading 0

Biotechnology Stock Review 2011:Update 1/2/12

Here are some key points from our 2011 Biotech Stock Review posted in Investor Uprising: Winners from the 2011 Rayno Life Science Portfolio: Abaxis (ABAX), Alexion(ALXN), Amgen (AMGN), Biogen(BIIB), Bristol-Myers (BMY),Celera(acquired),Cephalon (acquired) Cubist (CBST), Exact Scientific (EXAS),Gilead (GILD), BioETF (IBB), Immucor (acquired), Neogen (NEOG), Regeneron (REGN),Quidel (QDEL), Seattle Genetics (SGEN), United Therapeutics(UTHR) and Viropharma (VPHM) Losers: Alere […]

Continue Reading 0

Rayno Diagnostics and Tools Portfolio: ILMN, NEOG

Life Sciences: Biopharmaceutical Stocks are Hot, Tools and DX are Not We recommended avoiding the Tools/Dx sector several weeks ago as they were lagging biopharmaceutical stocks due to earnings misses, concerns about NIH finding for R&D, and lack of exciting new products. Illumina (ILMN $28.95) is up 6.5% today and has been volatile in the […]

Continue Reading 0

Three Small Cap Stocks for a Rebound in January: AMRI,ASTX,SRLS-UPDATE 1/5/12

January Rally on Schedule for Small Cap Biotech Stocks Three Picks we made on December 14: Albany Molecular (AMRI $2.89) Up 16% Astex Pharmaceuticals (ASTX $1.94) Up 19% SeraCare (SRLS $3.00) Up 1.7% Three healthcare conferences in San Francisco next week Jan. 9-13 should provide news and perhaps another boost for biotech stocks: J.P.Morgan Healthcare […]

Continue Reading 0

Macro News Kills Holiday Buzz: Markets Off 1.6% and More

Rally Hits a Wall at S&P Q4 High of 1265, Down 2%  to 1237 You have heard all the compelling reasons to jump into this market: Seasonality is strong from November through May Charts look good Lots of cash on the sidelines, everyone is underinvested Interest rates are too low for alternative investments- 10 yr. […]

Continue Reading 0